Results 61 to 70 of about 8,519 (204)

Effect of PRMT5 Expression Knockdown on Proliferation, Invasion and Apoptosis of Gastric Cancer Cells and Its Mechanism

Zhongliu Fangzhi Yanjiu, 2021
Objective To observe the expression level of PRMT5 in gastric cancer cells, and explore the effect of knocking down the expression level of PRMT5 on the biological behavior of gastric cancer cells.
GUO Ping, CHEN Jian, WANG Huaqiang, GE Kaijie   +3 more
doaj   +1 more source

Curcumin in the Treatment of Various Diseases: Mechanism of Action, Bioavailability, Therapeutic Effects, and Current Clinical Trials

MedComm, Volume 7, Issue 11, November 2026.
Curcumin, a naturally occurring polyphenol, exhibits significant anti‐inflammatory and antioxidant capabilities. This review elucidates the specific molecular mechanisms by which curcumin exerts therapeutic effects on various diseases, including neurological disorders, cardiovascular diseases, cancers, inflammatory disorders, and autoimmune diseases ...
Lin Wang, Qifei Pan, Wenjuan Long, Xinyao Li, Jianqin Mao, Sitong Zhou, Zihui Wang, Xuelian Zou, Yuqing She, Mingqin Shi, Yang Zhou, Jiarong Du, Zhongyang Hu, Xiaoman Lv, Yishu Chen, Dongdong Qin   +15 more
wiley   +1 more source

Antitumor Effects of PRMT5 Inhibition in Sarcomas

Cancer Research Communications, 2023
Abstract Patients with advanced soft-tissue sarcomas (STS) have few therapeutic options. Protein arginine methyltransferase 5 (PRMT5), an anticancer target, has been extensively investigated in recent years in epithelial tumors.
Stéphanie Verbeke, Aurélien Bourdon, Jean-Philippe Guegan, Laura Leroy, Vanessa Chaire, Elodie Richard, Alban Bessede, Antoine Italiano   +7 more
openaire   +2 more sources

The potential and challenges of targeting MTAP-negative cancers beyond synthetic lethality

Frontiers in Oncology, 2023
Approximately 15% of cancers exhibit loss of the chromosomal locus 9p21.3 – the genomic location of the tumour suppressor gene CDKN2A and the methionine salvage gene methylthioadenosine phosphorylase (MTAP).
Chandler Bray, Cristina Balcells, Iain A. McNeish, Hector C. Keun   +3 more
doaj   +1 more source

Targeted Protein Degradation: From Molecular Mechanisms to Emerging Therapeutic Strategies

MedComm, Volume 7, Issue 11, November 2026.
Graphical overview of targeted protein degradation: mechanisms, molecular determinants, delivery strategies, and therapeutic development. This graphical abstract summarizes the major degradation pathways involved in targeted protein degradation, including the ubiquitin–proteasome system, endocytosis–lysosome pathway, and autophagy‐dependent degradation.
Huaijuan Guo, Haishuang Duan, Yang Liu, Kelan Fang, Lujia Xiao, Ling Bai, Xiao Qu, Xuebing Yan, Kun Zhang   +8 more
wiley   +1 more source

Histone Modifications at the Intersection of Aging, Neuroinflammation and Metabolism in Alzheimer's Disease

Aging Cell, Volume 25, Issue 11, November 2026.
This review examines how histone modifications integrate aging, metabolic dysfunction and neuroinflammation to shape persistent, cell‐type‐specific chromatin states in Alzheimer's disease. By distinguishing causal regulation from association through perturbation, persistence and reversibility, it highlights metabolic–epigenetic feedback loops and ...
Junyi Liang, Huawen Cao, Xiumin Ren, Nan Sha, Xueqing Han, Ling Jiang, Bin Liu, Weiming Zhao   +7 more
wiley   +1 more source

PRMT5 is a therapeutic target in choroidal neovascularization

Scientific Reports, 2022
Abstract Ocular neovascular diseases including neovascular age-related macular degeneration (nvAMD) are widespread causes of blindness. Patients’ non-responsiveness to currently used biologics that target vascular endothelial growth factor (VEGF) poses an unmet need for novel therapies.
Anbukkarasi Muniyandi, Matthew Martin, Mengyao Sun, Kamakshi Sishtla, Nathan R Jensen, Aishat Motolani, Xiaoping Qi, Michael E Boulton, Lakshmi Prabhu, Tao Lu, Timothy W Corson   +10 more
openaire   +3 more sources

Genome-wide profiling of Prmt5 binding during 3T3-L1 adipogenesis

, 2023
This  study aims to determine the unique role of Prmt5 during  adipogenesis by profiling Prmt5’s chromatin binding sites genome-wide at  three time points during 3T3-L1 differentiation.
Sabriya Syed (14525993)
core   +1 more source

Discovery and Biological Characterization of PRMT5:MEP50 ProteinProtein Interaction Inhibitors [PDF]

, 2022
Protein arginine methyltransferase 5 (PRMT5) is a master epigenetic regulator and an extensively validated therapeutic target in multiple cancers. Notably, PRMT5 is the only PRMT that requires an obligate cofactor, methylosome protein 50 (MEP50), to ...
Xuehong Deng, Liang, Weida, Weida Liang, Mingji Dai, Asberry, Andrew M., Sheng Liu, Chang-Deng Hu, Dai, Mingji, Jun Wan, Sims, Hunter, Hu, Chang-Deng, Wan, Jun, Jiang, Wen, Wen Jiang, Liu, Sheng, Ulises Santiago, Andrew M. Asberry, Xu, Xueyong, Xueyong Xu, Deng, Xuehong, Carlos J. Camacho, Santiago, Ulises, Cai, Xinpei, Camacho, Carlos, Xinpei Cai, Hunter S. Sims   +25 more
core   +1 more source

Structure of the arginine methyltransferase PRMT5-MEP50 reveals a mechanism for substrate specificity.

PLoS ONE, 2013
The arginine methyltransferase PRMT5-MEP50 is required for embryogenesis and is misregulated in many cancers. PRMT5 targets a wide variety of substrates, including histone proteins involved in specifying an epigenetic code.
Meng-Chiao Ho, Carola Wilczek, Jeffrey B Bonanno, Li Xing, Janina Seznec, Tsutomu Matsui, Lester G Carter, Takashi Onikubo, P Rajesh Kumar, Man K Chan, Michael Brenowitz, R Holland Cheng, Ulf Reimer, Steven C Almo, David Shechter   +14 more
doaj   +1 more source